Table 1.
Baseline characteristics
| QD → BID (N = 29) | BID → QD (N = 32) | P Value | Overall (N = 61) | |
|---|---|---|---|---|
| Age (years) |
60.9 ± 9.8 |
61.1 ± 8.4 |
0.925 |
61.0 ± 9.0 |
| Onset age |
51.7 ± 10.8 |
51.8 ± 7.0 |
0.857 |
51.7 ± 8.9 |
| Sex (M:F) |
11:18 |
13:19 |
1.000 |
24:37 |
| mUPDRS |
20.0 ± 9.5 |
22.5 ± 8.6 |
0.170 |
21.3 ± 9.0 |
| Hoehn and Yahr stage |
2.1 ± 0.5 |
2.4 ± 0.7 |
0.063 |
2.2 ± 0.6 |
| Ropinirole PR dose after titration |
8.9 ± 5.6 |
11.0 ± 5.7 |
0.128 |
10.0 ± 5.7 |
| LEDD |
894.0 ± 392.8 |
865.9 ± 361.7 |
0.879 |
879.2 ± 373.9 |
| Epworth Sleep Scale |
6.1 ± 5.5 |
6.2 ± 5.9 |
0.353 |
6.1 ± 5.6 |
| Sleep questionnaire |
|
|
|
|
| Overall sleep quality |
3.8 ± 2.6 |
2.9 ± 2.7 |
0.232 |
3.4 ± 2.7 |
| Nocturnal off-symptoms |
2.5 ± 2.8 |
3.4 ± 3.7 |
0.659 |
3.0 ± 3.3 |
| Early morning off symptoms | 2.9 ± 2.7 | 3.0 ± 3.9 | 0.721 | 3.0 ± 3.8 |
QD, Once-daily; BID, Twice-daily; mUPDRS, Unified Parkinson’s Disease Rating Scale part 3; PR, prolonged-release; LEDD, levodopa equivalent dose.